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Analysis of effectiveness
The analysis was based on intention to treat. Primary health outcomes studied included the rate of GFR decline, the reduction in proteinuria, and the risk of progression. The baseline characteristics of patients in the two treatment groups were comparable.
Effectiveness results
The decline in GFR per month was significantly lower in the ramipril group than the control group (0.53 (0.8) versus 0.88 (0.13) mL/min, p=0.03).
Among the ramipril patients, the percentage reduction in proteinuria was inversely correlated with the decline in GFR, (p=0.035) and predicted the reduction in risk of doubling of baseline creatinine or endstage renal failure (18 ramipril versus 40 placebo, p=0.04).
The risk of progression was still significantly reduced after adjustment for changes in systolic, (p=0.04) and diastolic, (p=0.04) blood pressure, but not after adjustment for changes in proteinuria.
Clinical conclusions
In chronic nephropathies with proteinuria of 3g or more per 24 hours, ramipril safely reduces proteinuria and the rate of GFR declines to an extent that seems to exceed the reduction expected for the degree of blood-pressure lowering.
Modelling
A lifetime decision analytic model was used to determine the cost-effectiveness of the two treatment strategies.
Measure of benefits used in the economic analysis
The progression to ESRD and life expectancy were used as the measures of benefit. Benefits were discounted at an annual discount rate of 5%.
Direct costs
Direct costs were discounted at an annual discount rate of 5%. Quantities and costs were not reported separately. Direct costs related to all direct medical costs, including those for outpatient and inpatient care, medications, medical equipment, supplies, and laboratory tests. The quantity/cost boundary adopted was that of the health service. The estimation of quantities and costs was based on actual data. Costs were collected from studies published between 1990 and 1997. The price year was not reported.
Statistical analysis of costs
No statistical analysis was carried out.
Indirect Costs
Indirect costs were not included.
Currency

US dollars ($).
